drugset / Trial / NCT05456204
Refralon in Patients With Recurrence Paroxysmal and Persistent Forms of Atrial Fibrillation Who Underwent Catheter Ablation
Completed
120 enrolled
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
NaSingle-groupOpen-labelTreatment
Summary
It is planned to evaluate the efficacy and safety of the class III antiarrhythmic drug refralon as a drug for pharmacological cardioversion in patients with recurrent atrial fibrillation (AF) and atrial flutter (AFL) after catheter ablation.
Timeline
- Start
- 2022-02-15
- Primary completion
- 2024-06-30
- Completion
- 2024-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Refralon | Unknown | 30 ug/kg | Intravenous |